Lexeo Therapeutics (LXEO) Total Current Liabilities (2022 - 2026)

Lexeo Therapeutics has disclosed Total Current Liabilities across 5 years of filings, most recently posting $14.2 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $14.2 million, down 53.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.2 million (down 53.97% YoY), and the FY2025 annual result was $16.8 million, down 26.43% from the prior year.
• Total Current Liabilities came in at $14.2 million for Q1 2026 at Lexeo Therapeutics, down from $16.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $31.6 million in Q2 2025 to a low of $14.2 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $20.3 million (2024), against an average of $21.3 million.
• Across the five-year window, Total Current Liabilities surged 67.36% in 2025 and tumbled 53.97% in 2026, its largest moves.
• Lexeo Therapeutics' Total Current Liabilities stood at $14.3 million in 2022, then increased by 20.14% to $17.2 million in 2023, then jumped by 32.53% to $22.8 million in 2024, then decreased by 26.43% to $16.8 million in 2025, then dropped by 15.58% to $14.2 million in 2026.
• The last three Total Current Liabilities figures came in at $14.2 million (Q1 2026), $16.8 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.